Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Nivolumab

First Posted Date: 2017-07-24

Last Posted Date: 2018-08-14

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT03227432

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Ondansetron
Drug: Dexamethasone
Drug: Aprepitant
Drug: Olanzapine

First Posted Date: 2017-07-17

Last Posted Date: 2019-08-20

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 240

Registration Number: NCT03219710

Locations: 🇮🇳
Dr Bra Irch, Aiims, New Delhi, New Delhi, Delhi, India

Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery

Phase 3

Completed

Conditions: Major Non-cardiac Surgery

Interventions: Drug: Placebos
Drug: Dexamethasone

First Posted Date: 2017-07-14

Last Posted Date: 2020-06-01

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 1222

Registration Number: NCT03218553

Locations: 🇫🇷
Hôpital Beaujon, Clichy, France
🇫🇷
CHU La Cavale Blanche, Brest, France
🇫🇷
Hôpital Claude Huriez, Lille, France

and more 26 locations

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp alfa
Drug: Dexamethasone

First Posted Date: 2017-07-12

Last Posted Date: 2024-12-24

Lead Sponsor: Takeda

Target Recruit Count: 272

Registration Number: NCT03215030

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 91 locations

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Phase 3

Recruiting

Conditions: Mature B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab window
Drug: Cyclophosphamide
Drug: Additional doses of Rituximab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Doxorubicin hydrochloride
Drug: Ifosfamide
Drug: Vindesine Sulfate
Drug: Methotrexate
Drug: Prednisolone
Drug: Vincristine

First Posted Date: 2017-07-02

Last Posted Date: 2023-12-11

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 650

Registration Number: NCT03206671

Locations: 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭
Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭
Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Pomalidomide

First Posted Date: 2017-06-28

Last Posted Date: 2023-09-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 8

Registration Number: NCT03202628

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery

Phase 4

Terminated

Conditions: Dexamethasone
Carcinoma, Non-Small-Cell Lung
Flubiprofen Axetil
Delirium
Surgery--Complications

Interventions: Drug: Normal saline
Drug: Dexamethasone
Drug: Lipid microsphere
Drug: Flurbiprofen axetil

First Posted Date: 2017-06-27

Last Posted Date: 2021-07-13

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 126

Registration Number: NCT03200600

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy

Phase 3

Conditions: Bladder Cancer
Ureter Cancer
Transitional Cell Carcinoma

Interventions: Drug: pemetrexed
Drug: Folic Acid
Drug: Vitamin B12 Injection
Drug: Dexamethasone

First Posted Date: 2017-06-21

Last Posted Date: 2017-06-21

Lead Sponsor: Asan Medical Center

Target Recruit Count: 74

Registration Number: NCT03193788

Locations: 🇰🇷
Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Dong-A University Medical Center, Pusan, Korea, Republic of
🇰🇷
Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of

and more 18 locations

MUK Nine b: OPTIMUM Treatment Protocol

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Melphalan
Drug: Filgrastim

First Posted Date: 2017-06-15

Last Posted Date: 2024-05-14

Lead Sponsor: University of Leeds

Target Recruit Count: 95

Registration Number: NCT03188172

Locations: 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom

and more 18 locations

Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery

Phase 3

Withdrawn

Conditions: Pain, Postoperative

Interventions: Drug: Bupivacaine
Drug: Dexamethasone

First Posted Date: 2017-06-12

Last Posted Date: 2018-05-31

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT03183596

Locations: 🇺🇸
UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy